Hyseq Inc., Imperial Cancer Research Technology Ltd. deal

HYSQ obtained exclusive rights to ectoapyrase anticlotting agents from Imperial, a subsidiary of the Imperial Cancer Research Fund. The license complements HYSQ's own discovery of ectopyrase isoforms ...